0001341235-15-000001.txt : 20150129
0001341235-15-000001.hdr.sgml : 20150129
20150129144956
ACCESSION NUMBER: 0001341235-15-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20150129
DATE AS OF CHANGE: 20150129
EFFECTIVENESS DATE: 20150129
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-233108
FILM NUMBER: 15558526
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
D
1
primary_doc.xml
X0707
D
LIVE
0001341235
Aldeyra Therapeutics, Inc.
131 HARTWELL AVENUE
SUITE 320
LEXINGTON
MA
MASSACHUSETTS
02421
781-761-4904
DELAWARE
Aldexa Therapeutics, Inc.
Neuron Systems Inc
Corporation
true
Todd
C.
Brady
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Executive Officer
Director
Stephen
Tulipano
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Executive Officer
Scott
L.
Young
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Executive Officer
C. Boyd
Clarke
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Martin
J.
Joyce
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Gary
Phillips
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Ben
Bronstein
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Neal
Walker
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Jesse
I.
Treu
131 Hartwell Avenue
Suite 320
Lexington
MA
MASSACHUSETTS
02421
Director
Biotechnology
Decline to Disclose
- 06b
false
2015-01-14
false
true
true
false
0
18365820
7791560
10574260
The Total Offering Amount represents the shares of stock sold plus the exercise price of the warrants. The Total Amount Sold represents the shares of stock sold; the Total Remaining to be Sold represents the aggregate exercise price of the warrants.
false
16
0
0
0
false
Aldeyra Therapeutics, Inc.
Todd C. Brady
Todd C. Brady
President and Chief Executive Officer
2015-01-29